Magazine Article | October 1, 2020

COVID Revs Up The Antibiotics Space

Source: Life Science Leader

By Wayne Koberstein, Executive Editor, Life Science Leader magazine
Follow Me On Twitter @WayneKoberstein

NovaBiotics is a company now pivoting to develop its antimicrobials to fight COVID and COVID-related bacterial infections, starting in the lungs. COVID is a virus, but infection with it often creates opportunities for other types of microbes to invade patients and overcome their natural defenses.

The company’s CEO, Deborah O’Neil, shares some surprising information about the way COVID has enlivened not only her company’s area of business, but also the antibiotics space industrywide. Antibiotics has quickly morphed from the sleepy area we were all talking about just a few months ago — dominated by antibiotic resistance and skittish investors — to an awakened space generating new interest and investment from VCs to Big Pharmas, with added help from regulators.

VIEW THE MAGAZINE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Life Science Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: